Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia

Kozaburo Akiyoshi, Suzan Dziennis, Julie Palmateer, Xuefang Ren, Arthur Vandenbark, Halina Offner, Paco S. Herson, Patricia D. Hurn

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A key target for novel stroke therapy is the regulation of post-ischemic inflammatory mechanisms. Recent evidence emphasizes the role of T lymphocytes of differing subtypes in the evolution is ischemic brain damage. We have recently demonstrated the benefit of myelin antigen-specific immunodulatory agents known as recombinant T cell receptor ligands (RTLs) in a standard murine model of focal stroke. The aim of the current study was to extend this initial observation to RTL treatment in a therapeutically relevant timing after middle cerebral artery occlusion (MCAO) and verify functional benefit to complement histological outcome measures. We observed that the administration of mouse-specific RTL551 reduced infarct size and improved sensorimotor outcome when administered within a 3 h post-ischemic therapeutic window. RTL551 treatment reduced cortical, caudate putamen, and total infarct volume as compared to vehicle-treated mice. Using a standard behavioral testing repertoire, we observed that RTL551 reduced sensorimotor impairment 3 days after MCAO. Humanized RTL1000 (HLA-DR2 moiety linked to hMOG-35-55 peptide) also reduced infarct size in HLA-DR2 transgenic mice. These data indicate that this neuroantigen-specific immunomodulatory agent reduces damage when administered in a therapeutically relevant reperfusion timeframe.

Original languageEnglish (US)
Pages (from-to)404-410
Number of pages7
JournalTranslational Stroke Research
Volume2
Issue number3
DOIs
StatePublished - Sep 2011

Fingerprint

HLA-DR2 Antigen
Middle Cerebral Artery Infarction
T-Cell Antigen Receptor
Brain Ischemia
Stroke
Ligands
Putamen
Myelin Sheath
Transgenic Mice
Reperfusion
Observation
Outcome Assessment (Health Care)
T-Lymphocytes
Antigens
Peptides
Brain
Therapeutics

Keywords

  • Cerebral infarction
  • Cerebral ischemia
  • Immunotherapy
  • Inflammation
  • Middle cerebral artery occlusion
  • Mouse
  • Stroke
  • T lymphocyte

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia. / Akiyoshi, Kozaburo; Dziennis, Suzan; Palmateer, Julie; Ren, Xuefang; Vandenbark, Arthur; Offner, Halina; Herson, Paco S.; Hurn, Patricia D.

In: Translational Stroke Research, Vol. 2, No. 3, 09.2011, p. 404-410.

Research output: Contribution to journalArticle

Akiyoshi, Kozaburo ; Dziennis, Suzan ; Palmateer, Julie ; Ren, Xuefang ; Vandenbark, Arthur ; Offner, Halina ; Herson, Paco S. ; Hurn, Patricia D. / Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia. In: Translational Stroke Research. 2011 ; Vol. 2, No. 3. pp. 404-410.
@article{9769753fd8904dc3b7c432cd54332b55,
title = "Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia",
abstract = "A key target for novel stroke therapy is the regulation of post-ischemic inflammatory mechanisms. Recent evidence emphasizes the role of T lymphocytes of differing subtypes in the evolution is ischemic brain damage. We have recently demonstrated the benefit of myelin antigen-specific immunodulatory agents known as recombinant T cell receptor ligands (RTLs) in a standard murine model of focal stroke. The aim of the current study was to extend this initial observation to RTL treatment in a therapeutically relevant timing after middle cerebral artery occlusion (MCAO) and verify functional benefit to complement histological outcome measures. We observed that the administration of mouse-specific RTL551 reduced infarct size and improved sensorimotor outcome when administered within a 3 h post-ischemic therapeutic window. RTL551 treatment reduced cortical, caudate putamen, and total infarct volume as compared to vehicle-treated mice. Using a standard behavioral testing repertoire, we observed that RTL551 reduced sensorimotor impairment 3 days after MCAO. Humanized RTL1000 (HLA-DR2 moiety linked to hMOG-35-55 peptide) also reduced infarct size in HLA-DR2 transgenic mice. These data indicate that this neuroantigen-specific immunomodulatory agent reduces damage when administered in a therapeutically relevant reperfusion timeframe.",
keywords = "Cerebral infarction, Cerebral ischemia, Immunotherapy, Inflammation, Middle cerebral artery occlusion, Mouse, Stroke, T lymphocyte",
author = "Kozaburo Akiyoshi and Suzan Dziennis and Julie Palmateer and Xuefang Ren and Arthur Vandenbark and Halina Offner and Herson, {Paco S.} and Hurn, {Patricia D.}",
year = "2011",
month = "9",
doi = "10.1007/s12975-011-0085-1",
language = "English (US)",
volume = "2",
pages = "404--410",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "3",

}

TY - JOUR

T1 - Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia

AU - Akiyoshi, Kozaburo

AU - Dziennis, Suzan

AU - Palmateer, Julie

AU - Ren, Xuefang

AU - Vandenbark, Arthur

AU - Offner, Halina

AU - Herson, Paco S.

AU - Hurn, Patricia D.

PY - 2011/9

Y1 - 2011/9

N2 - A key target for novel stroke therapy is the regulation of post-ischemic inflammatory mechanisms. Recent evidence emphasizes the role of T lymphocytes of differing subtypes in the evolution is ischemic brain damage. We have recently demonstrated the benefit of myelin antigen-specific immunodulatory agents known as recombinant T cell receptor ligands (RTLs) in a standard murine model of focal stroke. The aim of the current study was to extend this initial observation to RTL treatment in a therapeutically relevant timing after middle cerebral artery occlusion (MCAO) and verify functional benefit to complement histological outcome measures. We observed that the administration of mouse-specific RTL551 reduced infarct size and improved sensorimotor outcome when administered within a 3 h post-ischemic therapeutic window. RTL551 treatment reduced cortical, caudate putamen, and total infarct volume as compared to vehicle-treated mice. Using a standard behavioral testing repertoire, we observed that RTL551 reduced sensorimotor impairment 3 days after MCAO. Humanized RTL1000 (HLA-DR2 moiety linked to hMOG-35-55 peptide) also reduced infarct size in HLA-DR2 transgenic mice. These data indicate that this neuroantigen-specific immunomodulatory agent reduces damage when administered in a therapeutically relevant reperfusion timeframe.

AB - A key target for novel stroke therapy is the regulation of post-ischemic inflammatory mechanisms. Recent evidence emphasizes the role of T lymphocytes of differing subtypes in the evolution is ischemic brain damage. We have recently demonstrated the benefit of myelin antigen-specific immunodulatory agents known as recombinant T cell receptor ligands (RTLs) in a standard murine model of focal stroke. The aim of the current study was to extend this initial observation to RTL treatment in a therapeutically relevant timing after middle cerebral artery occlusion (MCAO) and verify functional benefit to complement histological outcome measures. We observed that the administration of mouse-specific RTL551 reduced infarct size and improved sensorimotor outcome when administered within a 3 h post-ischemic therapeutic window. RTL551 treatment reduced cortical, caudate putamen, and total infarct volume as compared to vehicle-treated mice. Using a standard behavioral testing repertoire, we observed that RTL551 reduced sensorimotor impairment 3 days after MCAO. Humanized RTL1000 (HLA-DR2 moiety linked to hMOG-35-55 peptide) also reduced infarct size in HLA-DR2 transgenic mice. These data indicate that this neuroantigen-specific immunomodulatory agent reduces damage when administered in a therapeutically relevant reperfusion timeframe.

KW - Cerebral infarction

KW - Cerebral ischemia

KW - Immunotherapy

KW - Inflammation

KW - Middle cerebral artery occlusion

KW - Mouse

KW - Stroke

KW - T lymphocyte

UR - http://www.scopus.com/inward/record.url?scp=80052268543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052268543&partnerID=8YFLogxK

U2 - 10.1007/s12975-011-0085-1

DO - 10.1007/s12975-011-0085-1

M3 - Article

VL - 2

SP - 404

EP - 410

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 3

ER -